Who Paid My Doc
Michael Bueche
Glaucoma Specialist East Lansing, MI Medical Doctor
NPI 1154305563 CMS profile 367595
2001 Coolidge Rd, East Lansing, MI 48823
General payments
$265
Research payments
$0
Ownership & investment interest
$0
Through program year 2020, Michael Bueche of East Lansing, MI is reported in the CMS Open Payments database as having received $265 across 14 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 5th percentile of Glaucoma Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2020 | General | $21 | 1 | |
| 2019 | General | $244 | 13 |
Beside peers
- Michael Bueche
- Glaucoma Specialist median
- Middle half of Glaucoma Specialist
- National median
In program year 2025, general payments to Michael Bueche were reported at $0. Among 370 Glaucoma Specialist profiles paid that year, the median was $597 and the middle half received between $244 and $1,607.
Show as a table
| Year | Michael Bueche | Glaucoma Specialist median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $244 | $433 | $150–$1,170 | $163 |
| 2020 | $21 | $242 | $74–$693 | $114 |
| 2021 | $0 | $324 | $122–$936 | $132 |
| 2022 | $0 | $399 | $121–$1,081 | $149 |
| 2023 | $0 | $458 | $190–$1,208 | $160 |
| 2024 | $0 | $558 | $215–$1,359 | $164 |
| 2025 | $0 | $597 | $244–$1,607 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 2 drugsPart D claims
28
Drug cost
$859
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Timolol Maleate | Generic | 14 | $576 | |
| Latanoprost | Generic | 14 | $283 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.
Records
14 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Glaucoma Specialist in Michigan
Scott Piette
Glaucoma Specialist · East Lansing, MI
Emily Schehlein
Glaucoma Specialist · Brighton, MI
Roman Krivochenitser
Glaucoma Specialist · Grand Rapids, MI
Sonia Rana
Glaucoma Specialist · East Lansing, MI
My Le Shaw
Glaucoma Specialist · Fenton, MI
Stephen Walters
Glaucoma Specialist · Pleasant Ridge, MI
Related records
Glaucoma Specialist in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Glaucoma Specialist
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.